Stock of the Day

September 1, 2020

Horizon Therapeutics Public (HZNP)

$116.30
$0.00 (0.0%)
Market Cap: $26.63B

About Horizon Therapeutics Public

Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; Arrowhead Pharmaceuticals, Inc.; Q32 Bio Inc.; and Xeris Biopharma Holdings, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.

Horizon Therapeutics Public Bull Case

Here are some ways that investors could benefit from investing in Horizon Therapeutics Public Limited:

  • Horizon Therapeutics Public Limited has a diverse portfolio of 12 medicines targeting rare diseases, autoimmune conditions, and severe inflammatory diseases, which positions the company well in niche markets with less competition.
  • The company’s flagship product, TEPEZZA, has shown strong sales growth, indicating robust demand and a solid market presence in the treatment of thyroid eye disease.
  • Recent collaborations with innovative biotech firms such as HemoShear Therapeutics and Arrowhead Pharmaceuticals may enhance Horizon's research capabilities and expand its product pipeline, potentially leading to new revenue streams.
  • The current stock price of HZNP reflects a favorable valuation compared to its peers in the pharmaceutical industry, making it an attractive option for investors looking for growth opportunities.
  • Horizon Therapeutics Public Limited has a strong commitment to addressing critical health needs, which can enhance its reputation and lead to increased investor confidence and support.

Horizon Therapeutics Public Bear Case

Investors should be bearish about investing in Horizon Therapeutics Public Limited for these reasons:

  • The biotechnology sector is highly volatile, and Horizon Therapeutics Public Limited may face significant risks related to regulatory approvals and market competition, which could impact its stock performance.
  • Dependence on a limited number of key products, such as TEPEZZA and KRYSTEXXA, means that any adverse developments regarding these drugs could significantly affect the company's revenue and stock price.
  • Recent market trends indicate increasing pressure on drug pricing, which could impact profit margins for Horizon Therapeutics Public Limited's products, especially in a competitive landscape.
  • Potential challenges in scaling production and distribution for new therapies could hinder the company’s ability to meet market demand, affecting overall growth prospects.
  • Investors should be cautious of the company's historical volatility in stock performance, which may indicate underlying risks that could affect future returns.